Abstract 127P
Background
Patients (pts) with resectable TESCC with multi-station lymph node metastases derive unoptimistic overall survival benefit with neoadjuvant or postoperative adjuvant therapy. Camrelizumab (anti-PD-1) is standard of care as second-line therapy for advanced TESCC in China. We hypothesize that the addition of camrelizumab to neoadjuvant chemotherapy agents (albumin paclitaxel and carboplatin) will increase the pathological complete response (pCR) rate compared with historical controls.
Methods
This was an investigator-initiated trial for pts with newly diagnosed AJCC 8th resectable TESCC with multi-station lymph node metastases with a plan to have surgery. Pts received 2 courses of camrelizumab 200mg IV q3w added to carboplatin AUC=5 IV q3w plus albumin paclitaxel 100 mg/m2 IV qwk with surgery 4 wks after the last dose. The primary objective was pCR. Our primary endpoint will be reached if 5/52 (9.6%) planned pts have pCR.
Results
From 11/2019 to 6/2020, 11 pts were enrolled all of whom had surgery. Median age was 65 (55-72), 9.1% women, and 36.4% PD-L1 positive (≥1%, 22C3). Pre-surgical grade 3/4 toxicity occurred in 8/11pts, and treatment was delayed by an average of 5.7 days due to toxicities. Grade 3/4 toxicities were neutropenia (8/11), thrombocytopenia (2/11). All pts recovered well from pre-surgical toxicities.Our primary endpoint was met; the pCR (pT0N0M0) was achieved in 45.4% (5/11) and pT0 was 54.5% (6/11). Radiologic response rate was 90.9% (PR10,CR0). Pts with either PD-L1+ or PD-L1- had pCRs. R0 resection rate was 100% (11/11). The average intraoperative blood loss was 172ml and the average hospitalization time after operation was 9 days (7-12days).No patient developed anastomotic leak and died due to treatment-related toxicity.
Conclusions
The addition of camrelizumab to neoadjuvant chemotherapy agents (albumin paclitaxel and carboplatin) was well tolerated. The primary endpoint of pCR in at least 5/52 pts was surpassed with pCR in 5/11 pts post-surgery. The pCR was seen independent of PD-L1 score. The surprisingly good preliminary results have encouraged us to keep this phase II study ongoing.
Clinical trial identification
ChiCTR1900026240.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session